Ironwood Pharmaceuticals (IRWD) Competitors $1.27 +0.09 (+7.63%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.27 0.00 (0.00%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IRWD vs. ABBV, MYGN, VSTM, EBS, LXRX, XOMA, CDXS, CBIO, VNDA, and SGMOShould you be buying Ironwood Pharmaceuticals stock or one of its competitors? The main competitors of Ironwood Pharmaceuticals include AbbVie (ABBV), Myriad Genetics (MYGN), Verastem (VSTM), Emergent Biosolutions (EBS), Lexicon Pharmaceuticals (LXRX), XOMA Royalty (XOMA), Codexis (CDXS), Crescent Biopharma (CBIO), Vanda Pharmaceuticals (VNDA), and Sangamo Therapeutics (SGMO). These companies are all part of the "medical" sector. Ironwood Pharmaceuticals vs. Its Competitors AbbVie Myriad Genetics Verastem Emergent Biosolutions Lexicon Pharmaceuticals XOMA Royalty Codexis Crescent Biopharma Vanda Pharmaceuticals Sangamo Therapeutics AbbVie (NYSE:ABBV) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability. Do analysts prefer ABBV or IRWD? AbbVie currently has a consensus target price of $214.95, indicating a potential upside of 2.22%. Ironwood Pharmaceuticals has a consensus target price of $4.94, indicating a potential upside of 288.98%. Given Ironwood Pharmaceuticals' higher possible upside, analysts plainly believe Ironwood Pharmaceuticals is more favorable than AbbVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AbbVie 0 Sell rating(s) 6 Hold rating(s) 16 Buy rating(s) 5 Strong Buy rating(s) 2.96Ironwood Pharmaceuticals 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.14 Which has more volatility and risk, ABBV or IRWD? AbbVie has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Do insiders and institutionals believe in ABBV or IRWD? 70.2% of AbbVie shares are held by institutional investors. 0.3% of AbbVie shares are held by company insiders. Comparatively, 12.7% of Ironwood Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is ABBV or IRWD more profitable? AbbVie has a net margin of 6.45% compared to Ironwood Pharmaceuticals' net margin of -2.25%. AbbVie's return on equity of 699.66% beat Ironwood Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets AbbVie6.45% 699.66% 13.64% Ironwood Pharmaceuticals -2.25%-2.46%2.19% Which has better valuation and earnings, ABBV or IRWD? AbbVie has higher revenue and earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbbVie$56.33B6.59$4.28B$2.10100.14Ironwood Pharmaceuticals$351.41M0.58$880K-$0.05-25.40 Does the media prefer ABBV or IRWD? In the previous week, AbbVie had 114 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 114 mentions for AbbVie and 0 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 1.66 beat AbbVie's score of 1.13 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment AbbVie Positive Ironwood Pharmaceuticals Very Positive SummaryAbbVie beats Ironwood Pharmaceuticals on 14 of the 17 factors compared between the two stocks. Get Ironwood Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRWD vs. The Competition Export to ExcelMetricIronwood PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$205.51M$2.53B$5.81B$9.76BDividend YieldN/A1.67%4.39%4.06%P/E Ratio-25.3922.9031.3626.05Price / Sales0.58516.56387.8788.42Price / Cash25.68179.1038.0259.36Price / Book-0.675.939.536.60Net Income$880K$31.83M$3.26B$265.65M7 Day Performance23.30%1.89%2.14%2.00%1 Month Performance54.95%1.62%3.22%0.46%1 Year Performance-74.50%9.25%30.18%18.88% Ironwood Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRWDIronwood Pharmaceuticals4.6037 of 5 stars$1.27+7.6%$4.94+289.0%-74.5%$205.51M$351.41M-25.39220Positive NewsGap UpABBVAbbVie4.7664 of 5 stars$206.23-0.2%$214.95+4.2%+6.4%$365.13B$56.33B98.2155,000Trending NewsMYGNMyriad Genetics3.6162 of 5 stars$5.71flat$12.45+118.1%-78.6%$531.28M$837.60M-1.332,700VSTMVerastem3.0201 of 5 stars$7.97-3.0%$13.29+66.7%+269.1%$505.90M$10K-2.4350EBSEmergent Biosolutions4.6836 of 5 stars$9.06+2.5%$14.33+58.2%-3.1%$471.62M$1.04B3.702,420LXRXLexicon Pharmaceuticals2.0604 of 5 stars$1.21-2.4%$3.23+166.5%-35.0%$450.61M$31.08M-3.67140XOMAXOMA Royalty4.1364 of 5 stars$31.74+1.2%$69.50+119.0%+21.1%$379.19M$28.49M-20.4810Analyst RevisionHigh Trading VolumeCDXSCodexis3.6214 of 5 stars$3.00-0.3%$11.00+266.7%-5.6%$271.70M$59.35M-3.61250Gap UpCBIOCrescent Biopharma3.9969 of 5 stars$13.79flat$25.50+84.9%N/A$269.59M$10K-0.3950Positive NewsGap UpHigh Trading VolumeVNDAVanda Pharmaceuticals4.4059 of 5 stars$4.56+4.6%$16.50+261.8%-13.0%$257.63M$198.77M-4.04290Analyst ForecastSGMOSangamo Therapeutics2.5929 of 5 stars$0.59+1.6%$4.50+663.9%-31.6%$174.99M$57.80M-2.03480 Related Companies and Tools Related Companies AbbVie Alternatives Myriad Genetics Alternatives Verastem Alternatives Emergent Biosolutions Alternatives Lexicon Pharmaceuticals Alternatives XOMA Royalty Alternatives Codexis Alternatives Crescent Biopharma Alternatives Vanda Pharmaceuticals Alternatives Sangamo Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRWD) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ironwood Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access